STOCK TITAN
  1. Home
  2. News
  3. CLDX

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET.

A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 30 days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com


Stock CLDX logo
Celldex Therapeutics Inc.

NASDAQ:CLDX

CLDX Rankings

#1739 Ranked by Market Cap
#4135 Ranked by Stock Gains
N/A Ranked by Dividends

CLDX Latest News

Apr 17, 2024
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Mar 8, 2024
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Mar 5, 2024
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Mar 5, 2024
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 29, 2024
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

CLDX Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Hampton

About CLDX

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im